Gerresheimer (GXI) PT Set at €87.70 by JPMorgan Chase & Co.

Gerresheimer (ETR:GXI) received a €87.70 ($104.40) target price from investment analysts at JPMorgan Chase & Co. in a research report issued on Friday. The firm presently has a “buy” rating on the stock. JPMorgan Chase & Co.’s price objective points to a potential upside of 27.06% from the company’s current price.

A number of other research analysts have also weighed in on GXI. Berenberg Bank set a €75.00 ($89.29) price objective on shares of Gerresheimer and gave the company a “buy” rating in a research note on Monday, September 4th. Deutsche Bank set a €62.00 ($73.81) price objective on shares of Gerresheimer and gave the company a “neutral” rating in a research note on Tuesday, September 5th. Independent Research set a €68.00 ($80.95) price objective on shares of Gerresheimer and gave the company a “neutral” rating in a research note on Tuesday, September 5th. Hauck & Aufhaeuser set a €63.50 ($75.60) price objective on shares of Gerresheimer and gave the company a “neutral” rating in a research note on Thursday, September 21st. Finally, set a €65.00 ($77.38) price objective on shares of Gerresheimer and gave the company a “neutral” rating in a research note on Thursday, September 28th. One research analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the company. Gerresheimer presently has an average rating of “Hold” and an average target price of €71.47 ($85.08).

Gerresheimer (ETR GXI) opened at €69.02 ($82.17) on Friday. Gerresheimer has a one year low of €59.97 ($71.39) and a one year high of €78.25 ($93.15). The firm has a market cap of $2,130.00 and a P/E ratio of 48.95.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Week Herald and is the property of of Week Herald. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://weekherald.com/2017/12/29/gerresheimer-gxi-pt-set-at-87-70-by-jpmorgan-chase-co.html.

About Gerresheimer

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates through two divisions, Plastics & Devices, and Primary Packaging Glass. The Plastics & Devices division offers drug delivery systems, such as inhalers, pen systems, and injection systems; sterile and non-sterile prefillable syringe systems for pharmaceutical and biotech industries; and disposables for various analysis systems that are used in laboratories and medical practices, quick tests for patients in medical practices or hospitals, skin-prick aids and lancets for diabetics, disposables and components for dialysis machines, and catheters and surgical devices.

Analyst Recommendations for Gerresheimer (ETR:GXI)

Receive News & Ratings for Gerresheimer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gerresheimer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply